GSK (GSK) has formed a strategic collaboration with Oxford BioTherapeutics to discover antibody-based cancer treatments, the UK-based oncology company said Wednesday.
The multi-year collaboration leverages GSK's drug development capabilities and Oxford's OGAP-Verify discovery platform to identify potential candidates, which will be validated through joint research, Oxford said.
The deal entitles Oxford to receive an undisclosed upfront payment, potential milestone payments and sales royalties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.